Medication info
Empagliflozin and Metformin Extended-Release Tablets 25/1000 mg

Empagliflozin and Metformin Extended-Release Tablets 25/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
White and light pink double convex oval-shaped extended-release film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500098 · Approved 2025.01.13 · Insurance code 645907570

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this product based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this product once daily in the evening with a meal. Take one 10/1000 mg extended-release tablet or one 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain its extended-release properties, swallow this product whole; do not split, crush, grind, or chew it. This product may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medication. If a patient repeatedly reports finding this product in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications, such as insulin, the recommended initial total daily dose when taking this product is empagliflozin 10 mg and the patient's current metformin dose. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this product should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this product is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse Reactions and 6. Interactions.) Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this product and periodically thereafter. No dose adjustment is required for patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. For patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this product may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this product. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this product immediately. Older adults In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood glucose control issues in adults with type 2 diabetes
  • hyperglycemia
  • and symptoms related to cardiovascular diseases
View approved original text

This medication is used to improve blood glucose control in adults with type 2 diabetes by supporting dietary and exercise regimens. It is particularly effective for patients whose blood glucose levels are not adequately controlled, and should be used cautiously in patients with cardiovascular disease after consulting a specialist. The medication helps to stabilize blood glucose and aids in overall diabetes management.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this product based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this product once daily in the evening with a meal. Take one 10/1000 mg extended-release tablet or one 25/1000 mg extended-release tablet once daily. Patients taking the 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain its extended-release properties, swallow this product whole; do not split, crush, grind, or chew it. This product may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medication. If a patient repeatedly reports finding this product in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications, such as insulin, the recommended initial total daily dose when taking this product is empagliflozin 10 mg and the patient's current metformin dose. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this product should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this product is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. (See Precautions for Use, 4. Adverse Reactions and 6. Interactions.) Special populations Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this product and periodically thereafter. No dose adjustment is required for patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. For patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this product may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this product. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this product immediately. Older adults In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Precautions

This medication helps to lower blood glucose and is used in diabetes treatment. Serious and rare side effects such as lactic acidosis can occur while taking this medication, so caution is advised. When taking this medication with other diabetes medications, hypoglycemic symptoms may occur, so caution is necessary. It is recommended that patients with poor kidney function or heart problems, as well as those in acute infection or dehydrated states, avoid taking this medication. If surgery is planned or diagnostic tests involving contrast media will be performed, the medication should be discontinued for a certain period. Pregnant or nursing women should not use this medication. Elderly patients or those with impaired kidney function need to have their dose adjusted and kidney function monitored regularly. This medication can affect the body's fluid balance, so caution is required in cases of dehydration or potential fluid loss. During treatment, genital infections or urinary tract infections may occur, so consulting healthcare professionals immediately if symptoms arise is essential. Long-term use may lower vitamin B12 levels, so regular monitoring of vitamin levels is necessary. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking during treatment. During medication, monitor for symptoms of hypoglycemia and take appropriate actions immediately if they occur. Do not crush or chew the tablets; swallow them whole, and the tablet coating may appear in the stool, which is normal.

Side effects

  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decrease and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • reduced fluid volume
  • nausea
  • vomiting
Show 157 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbances
  • itching
  • rash
  • hives
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic adenocarcinoma
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • intestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuritis
  • headache
  • dizziness
  • positional dizziness
  • weakness
  • chest discomfort
  • chest pain
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • nasopharyngitis
  • herpes zoster
  • drowsiness
  • facial paralysis
  • memory disturbances
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disturbances
  • amnesia
  • fatigue
  • peripheral edema
  • facial edema
  • fever
  • chills
  • strange sensations
  • edema
  • pain
  • vascular stent stenosis
  • vascular stent thrombosis
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • otalgia
  • postural vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • macular fibrosis
  • ocular discomfort
  • ocular congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • residual phlegm
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternal fracture

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1°C and 30°C at room temperature to ensure the medication's efficacy over time.

Appearance and packaging

Appearance

White and light pink double convex oval-shaped extended-release film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.